Cargando…

Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles

Identifying germline BRCA1/2 mutation carriers is vital for reducing their risk of breast and ovarian cancer. To derive a serum miRNA-based diagnostic test we used samples from 653 healthy women from six international cohorts, including 350 (53.6%) with BRCA1/2 mutations and 303 (46.4%) BRCA1/2 wild...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elias, Kevin, Smyczynska, Urszula, Stawiski, Konrad, Nowicka, Zuzanna, Webber, James, Kaplan, Jakub, Landen, Charles, Lubinski, Jan, Mukhopadhyay, Asima, Chakraborty, Dona, Connolly, Denise C., Symecko, Heather, Domchek, Susan M., Garber, Judy E., Konstantinopoulos, Panagiotis, Fendler, Wojciech, Chowdhury, Dipanjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250543/ https://www.ncbi.nlm.nih.gov/pubmed/37291133 http://dx.doi.org/10.1038/s41467-023-38925-4

Ejemplares similares

A systemic approach to screening high-throughput RT-qPCR data for a suitable set of reference circulating miRNAs
por: Pagacz, Konrad, et al.
Publicado: (2020)

Extracellular miRNAs as Biomarkers of Head and Neck Cancer Progression and Metastasis
por: Nowicka, Zuzanna, et al.
Publicado: (2019)

Prediction of Radiation-Induced Hypothyroidism Using Radiomic Data Analysis Does Not Show Superiority over Standard Normal Tissue Complication Models
por: Smyczynska, Urszula, et al.
Publicado: (2021)

NormiRazor: tool applying GPU-accelerated computing for determination of internal references in microRNA transcription studies
por: Grabia, Szymon, et al.
Publicado: (2020)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer
por: Elias, Kevin M, et al.
Publicado: (2017)

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
por: Strickland, Kyle C., et al.
Publicado: (2016)

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
por: Rebbeck, Timothy R., et al.
Publicado: (2009)

A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers
por: Gockley, Allison, et al.
Publicado: (2022)

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers
por: Song, Yun, et al.
Publicado: (2019)

BRCA1/2 testing: therapeutic implications for breast cancer management
por: Tung, Nadine M., et al.
Publicado: (2018)

Association of circulating miRNAS in patients with Alstrőm and Bardet-Biedl syndromes with clinical course parameters
por: Zmyslowska, Agnieszka, et al.
Publicado: (2022)

Serum microRNAs – potent biomarkers for radiation biodosimetry
por: Tomasik, Bartłomiej, et al.
Publicado: (2018)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

BRCA1 testing
por: Górski, Bohdan, et al.
Publicado: (2008)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2)
por: Lubiński, Jan
Publicado: (2005)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3
por: Yang, Rachel L., et al.
Publicado: (2015)

Significance of Direct Confirmation of Growth Hormone Insensitivity for the Diagnosis of Primary IGF-I Deficiency
por: Smyczyńska, Joanna, et al.
Publicado: (2020)

Effectiveness, economical and safety aspects of growth hormone (GH) therapy in growth promoting doses in patients with isolated GH deficiency after the attainment of near-final height. Is there a need to modify the criteria of therapy withdrawal?
por: Smyczyńska, Joanna, et al.
Publicado: (2021)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers
por: Marciniak, Wojciech, et al.
Publicado: (2021)

Impact of processing method on donated human breast milk microRNA content
por: Smyczynska, Urszula, et al.
Publicado: (2020)

Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers
por: Friedman, Eitan, et al.
Publicado: (2006)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2005)

Pre-treatment growth and IGF-I deficiency as main predictors of response to growth hormone therapy in neural models
por: Smyczyńska, Urszula, et al.
Publicado: (2017)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
por: Złowocka-Perłowska, Elżbieta, et al.
Publicado: (2022)

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
por: Tung, Nadine, et al.
Publicado: (2010)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Detection of a novel mutation in exon 20 of the BRCA1 gene
por: Chakraborty, Abhijit, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kb8colnuhoci8vr0t6hvbspm41